Treatment for glioblastoma (GBM)
Intended for US audiences only.
Optune® Novocure™

Optune®: Study in recurrent GBM

For people with recurrent GBM, a large clinical study has shown that Optune is as effective as chemotherapy, with patients self-reporting better quality of life.


Optune is as effective as chemotherapy in a clinical trial

In a large clinical trial of patients with recurrent GBM, Optune was shown to be as effective as chemotherapy. Patients using Optune and those receiving chemotherapy lived for a median* of about 6 months.

Median survival on chemotherapy was 6 months. Median survival on Optune® was 6.6 months.

*The median was the point where half of the patients in a group were still alive.

Quality of life

Compared to people who took chemotherapy, people who used Optune in a clinical trial self-reported better quality of life, with improved cognitive and emotional functioning.

Side effects

The most common (≥10%) side effects that people with recurrent GBM reported while using Optune alone in a clinical trial were scalp irritation from device use and headache. Optune was not shown to cause many of the most common (≥10%) side effects of chemotherapy.

The following adverse reactions were considered related to Optune when using the device alone: scalp irritation from device use, headache, malaise, muscle twitching, fall and skin ulcer.

Optune® side effects are scalp irritation and headache. Chemotherapy side effects are headache, malaise, low blood platelet count, nausea, and diarrhea.

Before you start therapy with Optune, you'll want to consider some of the potential benefits and side effects. For people with recurrent GBM, Optune is used alone. Some of the benefits of Optune may vary based on where you are in your diagnosis and treatment plan.


The benefits of Optune® are that compared with people who took chemotherapy, people who used Optune reported a better quality of life, it treats where the tumor is, and it is a portable therapy. The most common side effects that people reported while using Optune alone were scalp irritation from device use and headache.

Please click here to see the Optune Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.

1. Optune Instructions For Use. Novocure 2016.
2. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192-2202.

Would you like to contact a Novocure representative?


Contact us

Hear James’ perspective

Learn about his journey with recurrent GBM and Optune.

Watch the video
Find a Treatment Center

OPT-041.2-06


CONTACT AN OPTUNE EXPERT

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery and completion of radiation therapy together with concomitant standard of care chemotherapy.

For the treatment of recurrent GBM, Optune is indicated following histologically-or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

Important Safety Information

Contraindications

Do not use Optune if you have an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune if you are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

Use Optune only after receiving training from qualified personnel, such as your doctor, a nurse, or other medical personnel who have completed a training course given by Novocure (the device manufacturer).

Do not use Optune if you are pregnant, you think you might be pregnant or are trying to get pregnant. It is not known if Optune is safe or effective in these populations.

The most common (≥10%) adverse events involving Optune in combination with temozolomide were low blood platelet count, nausea, constipation, vomiting, fatigue, scalp irritation from device use, headache, convulsions, and depression.

The most common (≥10%) adverse events seen when using Optune alone were scalp irritation from device use and headache.

The following adverse reactions were considered related to Optune when using the device alone: scalp irritation from device use, headache, malaise, muscle twitching, fall and skin ulcer.

All servicing procedures must be performed by qualified and trained personnel.

Do not use any parts that do not come with the Optune Treatment Kit, or that were not sent to you by the device manufacturer or given to you by your doctor.

Do not wet the device or transducer arrays.

If you have an underlying serious skin condition on the scalp, discuss with your doctor whether this may prevent or temporarily interfere with Optune treatment.


Please click here to see the Optune Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.

Patient Journey videos on this site depict actual patients and caregivers. All other depictions of patients, caregivers, and healthcare professionals are actor portrayals.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).